Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel-group, Phase III Study of MRA-SC in Rheumatoid Arthritis Patients with Inadequate Response to Tocilizumab Subcutaneous Injection 162 mg every 2 weeks

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Parallel-group, Phase III Study of MRA-SC in Rheumatoid Arthritis Patients with Inadequate Response to Tocilizumab Subcutaneous Injection 162 mg every 2 weeks

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SHINOBI
  • Sponsors Chugai Pharmaceutical

    • Most Recent Events

    • 26 Jun 2017 According to a Chugai Pharmaceutical media release, the company obtained an approval by the Ministry of Health, Labour and Welfare (MHLW) for the additional dosage and administration of Actemra Subcutaneous Injection, reducing the dose interval to one week in patients with rheumatoid arthritis who inadequately respond to the bi-weekly dosage.
    • 16 May 2017 Status changed from active, no longer recruiting to completed.
    • 25 Aug 2016 According to a Chugai Pharmaceutical media release, the company filed an application with the Ministry of Health, Labour and Welfare (MHLW) for the approval of an additional dosage of Actemra (Tocilizumab) Subcutaneous injection in patients with rheumatoid arthritis who inadequately respond to the every other week dosing regimen.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top